http://www1.easl.eu/easl2011/program/Posters/Abstract991.htm
Conclusions: Four weeks of oral treatment with the TLR7 agonist GS-9620 in woodchucks chronically infected with WHV resulted in a sustained, marked reduction in serum levels of viral DNA and WHsAg and in the induction of an anti-WHs antibody response. These results suggest GS-9620 can induce a protective anti-viral immune response during chronic active hepadnaviral infection and has potential for use in the treatment of chronic hepatitis B.
This Study Was Supported by Contract N01-AI-05399 from the National Institute of Allergy and Infectious Diseases (NIAID), College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
producer glilead, how come the market is always in the hands of the same producers?gilead makes adv and tnf...phase 1 maybe out in 2017 at tnf patent expire